Clinical trials: Viremia
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
HIV Viremia, HIV -1 Infection
PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY
The study aims to increase the reach of the person-centred interpersonal practices by developing and accessing a tailored, scalable, and sustainable approach that meets the distinctive needs of populations identified as most…
- Trial name
- P-CoRE (NCT07021092)
- Testing
- Interventions will be developed in aim 2 of the study.
- Where
- 2 sites in Zambia
- Volunteers
- 3,000 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
Viremia, Bacteremia
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1.
- Conditions
- Viremia, Bacteremia, Acute Rejection of Renal Transplant
- Trial name
- NCT05799716
- Testing
- IVIG
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Hepatitis B
Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients
The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.
- Trial name
- NCT00051038
- Testing
- Entecavir
- Where
- 5 sites in United States
- Sponsor
- Bristol-Myers Squibb
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Chronic
Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV
Current treatments for Hepatitis C virus (HCV) have severe side effects and are very expensive. There is a need to explore effective natural therapies against HCV that are less toxic and more cost-effective.
- Trial name
- NCT02690103
- Testing
- pegylated IFN, Biobran, Ribavirin
- Volunteers
- 37 people
- Sponsor
- Cairo University
Cmv Congenital, CMV Viremia
Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation
The objectives of the protocol are to determine if a structured cognitive-behavioral interventional counseling of pregnant women can limit acquisition of human cytomegalovirus (HCMV) during pregnancy that we believe, will in turn…
- Trial name
- CMV (NCT03443791)
- Testing
- Women Enrolled, Newborns of Female Study Participants
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
CMV, AdV Infection
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
- Conditions
- CMV, AdV Infection, AdV Reactivation, Adenovirus
- Trial name
- NCT07225972
- Testing
- Standard of Care Antiviral medications, Viral CTLs
- Where
- 2 sites in United States
- Volunteers
- 138 people
- Sponsor
- New York Medical College
CMV Viremia, Transplantation Infection
CMV Infection and Immune Intervention After Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT.
- Trial name
- NCT04320303
- Testing
- expanded NK cells
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
HIV
Emtricitabine/Tenofovir Alafenamide as Salvage ART
Background: HIV attacks the immune system. Antiretroviral therapy (ART) is a combination of drugs used for treating HIV infection. For some people, ART drugs stop working against their HIV.
- Trial name
- NCT02556333
- Testing
- FTC/TAF
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV - Human Immunodeficiency Virus
Improving Management of Recipients of Care With HIV Viremia to Optimize Viral Suppression in Zambia: A Process and Outcome Evaluation
The Centre for Infectious Disease Research in Zambia (CIDRZ) as an implementing partner (IP) through its Centers for Disease Control and Prevention (CDC) and President's Emergency Plan for AIDS Relief (PEPFAR)-funded programs…
- Trial name
- NCT07747987
- Testing
- additional support
- Where
- Zambia
- Volunteers
- 548 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
Heart Failure
HCV Positive Heart Donors
Study subjects active on the waiting list for a heart transplant at the NYU Langone Transplant Institute who are hepatitis C (HCV) negative will receive a heart transplant from a donor who tests positive for HCV.
- Trial name
- NCT03382847
- Testing
- Transplant with HCV positive donor, followed by surveillance and treatment of viremia
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
HIV Infections
HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs
The purpose of this study is to gain information on how the type and amount of HIV present in certain places in the body and in the blood are affected when potent (powerful) anti-HIV drugs are given.
- Trial name
- NCT00007488
- Where
- 23 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation
A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-center, prospective, randomized, open-label clinical trial with blinded endpoint assessment for patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
- Trial name
- NCT07703657
- Testing
- Rituximab (Arm A), Standard Post-Transplant Supportive Care
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Yang Donglin
Cytomegalovirus Viraemia
Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)
This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems.
- Trial name
- ID-MAGIC (NCT06574789)
- Testing
- Standard dosing of IV ganciclovir, Personalised dosing of IV ganciclovir
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 232 people
- Sponsor
- Murdoch Childrens Research Institute
Cytomegalovirus
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. T-cells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT01646645
- Testing
- CMV-pp65 CTLs
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
EBV-induced Lymphomas, EBV-associated Malignancies
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
This is a Phase II trial to evaluate the efficacy and safety of human leukocyte antigen (HLA) partially-matched third-party allogeneic Epstein-Barr virus cytotoxic T lymphocytes (EBV-CTLs) for the treatment of EBV-induced…
- Conditions
- EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
- Trial name
- NCT01498484
- Testing
- EBV-specific T cells (EBV-CTLs)
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Atara Biotherapeutics
Cytomegalovirus Viremia, Cytomegalovirus Pneumonia
CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency
Treatment of CMV in a patient with profound combined immunodeficiency, who has viremia and pneumonia, using CMV-specific donor-derived T lymphocytes (CMV-VST).
- Conditions
- Cytomegalovirus Viremia, Cytomegalovirus Pneumonia, T-Lymphocyte Immunodeficiency
- Trial name
- NCT07015801
- Testing
- CMV-VST
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of Calgary